New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTSTAA, STAA, STAA, VTL, VTL, VTL, ANAC, ANAC, ANAC, PTCT, PTCT, PTCT, SGMO, SGMO, SGMO, RNA, RNA, RNA, BLUE, BLUE, BLUE, BIND, BIND, BIND, FCSC, FCSC, FCSC, CRDC, CRDC, CRDC, DRTX, DRTX, DRTXWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
News For DRTX;CRDC;FCSC;BIND;BLUE;RNA;SGMO;PTCT;ANAC;VTL;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
13:59 EDTPTCTNHS to wait on NICE to make call on PTC Therapeutics, BioMarin drugs
NHS England has set out its planned investment decisions for certain specialized services as part of its annual commissioning round. NHS England has agreed with the recommendations from CPAG that final funding decisions on the following two treatments should be made after NICE has concluded its Highly Specialized Technology Appraisal process: BioMarin Pharmaceutical's (BMRN) Vimizim for Morquio A Syndrome and PTC Therapeutics' (PTCT) Translarna for Duchenne muscular dystrophy. The decisions on those two drugs came among 39 proposed new investments that the group said were "carefully considered against the principles NHS England follows when making investment decisions." Reference Link
July 1, 2015
07:40 EDTANACAnacor price target raised to $80 from $70 at Jefferies
Jefferies analyst David Steinberg raised his price target for Anacor Pharmaceuticals to $80 from $70 saying Kerydin continues to exceed expectations. Sandoz has now fully completed its planned sales force expansion for the toenail fungus treatment, Steinberg tells investors in a research note, citing his industry contacts. Further, pivotal AN2728 Phase 3 data is expected in the coming weeks, the analyst points out. He ascribes 80% odds to a positive readout for the atopic dermatitis candidate, which he feels could push the shares past $100. Steinberg keeps a Buy rating on Anacor.
June 30, 2015
09:15 EDTANACAnacor price target raised to $85 from $72 at Wedbush
Wedbush believes that sales of Anacor's Kerydin drug have been impressive and could cause the company's Q2 results to beat expectations. The firm significantly raised its 2015-2017 Kerydin sales estimates and keeps an Outperform rating on Anacor.
07:03 EDTBLUECelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
June 29, 2015
18:09 EDTBLUEJuno surges after Celgene collaboration, CAR-T peers follow
Subscribe for More Information
08:35 EDTANACAnacor announces amendment to KERYDIN commercialization agreement
Subscribe for More Information
June 24, 2015
09:07 EDTBLUECAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:06 EDTBLUEbluebird bio 2.94M share Spot Secondary priced at $170.00
Subscribe for More Information
June 23, 2015
16:01 EDTBLUEbluebird bio files to sell $400M in common stock
Subscribe for More Information
09:14 EDTBINDOn The Fly: Pre-market Movers
Subscribe for More Information
07:49 EDTPTCTPTC Therapeutics risk lowered by symposium, says Oppenheimer
Subscribe for More Information
07:31 EDTBINDBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
June 22, 2015
10:16 EDTBINDBIND Therapeutics names Andrew Hirsch as president and CEO
BIND Therapeutics announced that Andrew Hirsch has been appointed president and CEO of the company. Hirsch had been serving in the role on an acting basis since March. Hirsch has also been elected to BIND’s Board of Directors. “After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the company’s growth,” said Daniel Lynch, Chairman, BIND Therapeutics Board of Directors.
08:03 EDTBLUEKite Pharma, bluebird bio announce strategic collaboration
Subscribe for More Information
June 19, 2015
13:38 EDTBLUEOptions with decreasing implied volatility
Options with decreasing implied volatility: QIHU PIR RHT BLUE KMX RAD KBH ADBE ACM KR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use